KR20220164539A - SARS-CoV-2 감염의 치료를 위한 25-히드록시비타민 D - Google Patents

SARS-CoV-2 감염의 치료를 위한 25-히드록시비타민 D Download PDF

Info

Publication number
KR20220164539A
KR20220164539A KR1020227038282A KR20227038282A KR20220164539A KR 20220164539 A KR20220164539 A KR 20220164539A KR 1020227038282 A KR1020227038282 A KR 1020227038282A KR 20227038282 A KR20227038282 A KR 20227038282A KR 20220164539 A KR20220164539 A KR 20220164539A
Authority
KR
South Korea
Prior art keywords
hydroxyvitamin
day
subject
days
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227038282A
Other languages
English (en)
Korean (ko)
Inventor
찰스 더블유. 비숍
스테판 에이. 스트러그넬
아크타르 아쉬파오
림 엘라메인 엘시디그
콜름 눌티
Original Assignee
에어젠 파마 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에어젠 파마 엘티디. filed Critical 에어젠 파마 엘티디.
Publication of KR20220164539A publication Critical patent/KR20220164539A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
KR1020227038282A 2020-04-06 2021-04-06 SARS-CoV-2 감염의 치료를 위한 25-히드록시비타민 D Pending KR20220164539A (ko)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202063006034P 2020-04-06 2020-04-06
US63/006,034 2020-04-06
US202063006563P 2020-04-07 2020-04-07
US63/006,563 2020-04-07
US202063009155P 2020-04-13 2020-04-13
US63/009,155 2020-04-13
US202063012781P 2020-04-20 2020-04-20
US63/012,781 2020-04-20
US202063032714P 2020-05-31 2020-05-31
US63/032,714 2020-05-31
PCT/IB2021/000220 WO2021205225A1 (en) 2020-04-06 2021-04-06 25-hydroxyvitamin d for the treatment of sars-cov-2 infection

Publications (1)

Publication Number Publication Date
KR20220164539A true KR20220164539A (ko) 2022-12-13

Family

ID=75904967

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227038282A Pending KR20220164539A (ko) 2020-04-06 2021-04-06 SARS-CoV-2 감염의 치료를 위한 25-히드록시비타민 D

Country Status (8)

Country Link
US (2) US20210308151A1 (cg-RX-API-DMAC7.html)
EP (1) EP4132477A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023520591A (cg-RX-API-DMAC7.html)
KR (1) KR20220164539A (cg-RX-API-DMAC7.html)
CN (1) CN116033940A (cg-RX-API-DMAC7.html)
CA (1) CA3176559A1 (cg-RX-API-DMAC7.html)
TW (1) TW202203936A (cg-RX-API-DMAC7.html)
WO (1) WO2021205225A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2862462B2 (es) * 2020-04-06 2023-04-27 Servicio Andaluz De Salud Compuestos para la profilaxis y/o el tratamiento del sindrome de dificultad respiratoria aguda
CA3181945A1 (en) * 2020-05-31 2021-12-09 Eirgen Pharma Ltd. Hard capsule dosage form and uses thereof
CN116785295A (zh) * 2023-06-29 2023-09-22 吉林大学 雷特格韦在防治新型冠状病毒感染药物中的应用
WO2025094144A1 (en) 2023-11-02 2025-05-08 Eirgen Pharma Ltd. Controlling loss of kidney function

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264223A (en) 1990-03-29 1993-11-23 Japan Elanco Company, Ltd. Hard capsule for pharmaceutical drugs and method for producing the same
US5431917A (en) 1992-10-08 1995-07-11 Japan Elanco Company, Ltd. Hard capsule for pharmaceutical drugs and method for producing the same
FR2757173A1 (fr) 1996-12-17 1998-06-19 Warner Lambert Co Compositions polymeres d'origine non-animale pour la formation de films
KR100379674B1 (ko) 2000-03-06 2003-04-10 주식회사 서흥캅셀 펙틴과 글리세린의 배합용액을 이용한 셀룰로오스 캅셀 및그의 제조방법
PT3095447T (pt) * 2006-02-03 2022-01-24 Opko Renal Llc Tratamento da insuficiência e deficiência de vitamina d com 25-hidroxivitamina d2 e 25-hidroxivitamina d3
CA2651283A1 (en) 2006-05-15 2007-11-22 Wisconsin Alumni Research Foundation Pulmonary delivery of 1.alpha.,25-dihydroxyvitamin d3 and co-administration of parathyroid hormone or calcitonin
FR2902092B1 (fr) 2006-06-07 2008-09-05 Sapelem Soc Par Actions Simpli Appareil de manutention de charge
KR101691876B1 (ko) * 2007-04-25 2017-01-02 사이토크로마 인코포레이티드 비타민 d 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 d 방출 제형
CR20170085A (es) * 2014-08-07 2017-04-25 Opko Ireland Global Holdings Ltd Terapia adjuntiva con 25-hidroxi vitamina d
KR20180123100A (ko) * 2016-03-28 2018-11-14 옵코 아일랜드 글로벌 홀딩스 리미티드 비타민 d 치료 방법
EP3843706A1 (en) 2018-08-31 2021-07-07 OPKO Ireland Global Holdings, Ltd. Vitamin d pediatric dosage forms, methods of making and using

Also Published As

Publication number Publication date
WO2021205225A1 (en) 2021-10-14
TW202203936A (zh) 2022-02-01
US20250144119A1 (en) 2025-05-08
CA3176559A1 (en) 2021-10-14
US20210308151A1 (en) 2021-10-07
JP2023520591A (ja) 2023-05-17
WO2021205225A8 (en) 2023-01-05
CN116033940A (zh) 2023-04-28
EP4132477A1 (en) 2023-02-15

Similar Documents

Publication Publication Date Title
US20250144119A1 (en) Activating endogenous antimicrobials to treat sars-cov-2 infection
JP5398268B2 (ja) タイトジャンクション・エフェクター用製剤
US20220193010A1 (en) Methods of using dipivefrin
TW202206079A (zh) 治療嗜伊紅性食道炎之方法
US8080528B2 (en) Compositions and methods for treatment of cachexia
JP2019528272A5 (cg-RX-API-DMAC7.html)
CN107405309A (zh) 用于治疗肥胖症和相关代谢紊乱的奥利司他和阿卡波糖的调释组合物
US11534404B2 (en) Multilayer beads for pharmaceutical use
KR20140121394A (ko) 아캄프로세이트 제제, 그것의 사용 방법, 및 그것을 포함하는 조합
US20230330110A1 (en) Hard capsule dosage form and uses thereof
JP2025522785A (ja) 多発性硬化症及び重症筋無力症に対する治療用チロシンキナーゼ阻害剤
US20140329782A1 (en) Combined therapeutic agent
EP3421033B1 (en) Hiv treatment formulation of atazanavir and cobicistat
KR101430089B1 (ko) 류마티스 질환의 지연-방출형 글루코코르티코이드 치료제
TW202203934A (zh) 治療涉及全身過度發炎性反應的病症的受體相互作用蛋白激酶抑制劑
WO2021195119A1 (en) Methods of reducing the risk of, severity of, and treating coronavirus infections
TWI728959B (zh) 不穩定或難溶藥物的口服投予
US20240009154A1 (en) Methods and compositions for treating cytokine release syndrome
WO2021132302A1 (ja) 透析移行又は腎死の抑制のための薬剤
US20210205325A1 (en) Methods of treating a subject having an infectious disease
ES2862462B2 (es) Compuestos para la profilaxis y/o el tratamiento del sindrome de dificultad respiratoria aguda
CN121985954A (zh) 用于减少与体重减轻相关的肌肉减少和/或抑制肌肉减少症的方法和组合物
EP4326279A1 (en) Universal dosage regime of 25-hydroxy vitamin d3
HK40002830A (en) Hiv treatment formulation of atazanavir and cobicistat
TW200840590A (en) Compositions and methods for prevention and treatment of cachexia

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902